Actually, I don't think in the end we'll see a KM curve that compares the DCVax-L treatment arm to the control arm of "a" or "combination of" specific past trials. Instead, I think they'll assemble a much larger compilation of control patients from other comparable trials or historical groupings whose data is statistically familiar to the patients in the DCVax-L trial. So for all we know, if there are patients from the check mate methylated patients matches the data from the DC Vax trial, they may pull from that trial for the control comparison as well. But what they won't be doing is comparing the DCVax-L treatment arm that is comprised of some specific combination both methylated and unmethylated patients, and comparing it to the control arm of the checkmate methylated only trial.
So instead of comparing to a like number of comparable control patients (99), they'll probably assemble a much larger group of comparable control patients and compare the 232 DCVax-L treatment arm to them. And guess what? I bet the DCVax-L treatment arm still beats, even when comparing to this much larger number of comparable control patients.
But we shall see. I wonder if Fife has seen? If he did, then he placed another $15 million bet down on NWBO to get his money back, and then some.
Market Data 
Markets 
